LILRB2

Across TCGA pan-cancer cohorts, LILRB2 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated LILRB2 data layer compared with 25 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher LILRB2 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated LILRB2 expression acts as an unfavorable survival marker, although some lineages such as LSCC and HNSC show a favorable association.

CCRCC, LUAD, and LSCC are the cancer types where LILRB2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Tertile	II,III,IV	0.535	1.000	.002	28	view →
LUAD	OS	Median	II,III,IV	0.337	0.908	.002	17	view →
LSCC	DFS	Median	III,IV	0.988	0.583	.018	13	view →
UCEC	DFS	Tertile	All	0.601	1.000	.019	8	view →
PDAC	OS	Tertile	All	0.589	0.958	.020	3	view →
HNSC	DFS	Tertile	III,IV	1.000	0.623	.040	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

LILRB2–CCRCC (OS)

Open the CCRCC breakdown →